CDA | Evidence Driven
CDA | Evidence Driven

insulin icodec

Details

Files
Generic Name:
insulin icodec
Project Status:
Active
Therapeutic Area:
Diabetes mellitus, type 2
Manufacturer:
Novo Nordisk Canada Inc.
Call for patient/clinician input open:
Brand Name:
Awiqli
Project Line:
Reimbursement Review
Project Number:
SR0790-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The once-weekly treatment of adults with type 2 diabetes mellitus to improve glycemic control.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​The once-weekly treatment of adults with diabetes mellitus to improve glycemic control.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open06-Sep-23
Call for patient/clinician input closed30-Oct-23
Clarification:

- Patient input submission received from Diabetes Canada

Submission received18-Oct-23
Submission accepted-
Review initiated02-Nov-23
Draft CADTH review report(s) provided to sponsor for comment01-Feb-24
Deadline for sponsors comments12-Feb-24
CADTH review report(s) and responses to comments provided to sponsor14-Mar-24
Expert committee meeting (initial)27-Mar-24
Draft recommendation issued to sponsor11-Apr-24
Draft recommendation posted for stakeholder feedback18-Apr-24
End of feedback period03-May-24
Final recommendation issued to sponsor and drug plans17-May-24
Final recommendation posted05-Jun-24
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)03-Jun-24
CADTH review report(s) posted-

Files

Recommendation and Reason View PDF
Patient and Clinician Group input View PDF
Last Updated : September 5, 2024